s0329, gemcitabine and paclitaxel in treating patients with persistent, recurrent, or metastatic head and neck cancer

Conditions: Head and Neck Cancer

Summary: rationale: drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving gemcitabine together with paclitaxel may kill more tumor cells. purpose: this phase ii trial is studying how well giving gemcitabine together with paclitaxel works in treating patients with persistent, recurrent, or metastatic head and neck cancer.

objectives: * determine overall and progression-free survival probability in patients with persistent, recurrent, or metastatic squamous cell carcinoma of the head and neck treated with gemcitabine and paclitaxel. * determine the confirmed and unconfirmed response (partial and complete) probability in patients with measurable disease treated with this regimen. * determine the toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive gemcitabine iv over 30 minutes and paclitaxel iv over 1 hour on days 1 and 15. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. patients with a complete response (cr) receive 4 additional courses beyond cr. patients are followed every 8 weeks until disease progression, every 6 month for 2 years, and then annually for 1 year. projected accrual: a total of 65 patients will be accrued for this study within 10-13 months.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed squamous cell carcinoma of the head and neck (scchn) * recurrent, persistent, or newly diagnosed metastatic disease * measurable or non-measurable disease * no active or prior cns metastasis patient characteristics: age * 18 and over performance status * zubrod 0-1 life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * no serious organ dysfunction * no serious comorbid conditions that would preclude study treatment * no history of hypersensitivity reaction to products containing polysorbate 80 * no active infection requiring systemic antibiotic therapy * no symptomatic sensory neuropathy ≥ grade 2 * no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * not pregnant or nursing * fertile patients must use effective contraception prior concurrent therapy: biologic therapy * no concurrent biologic or immunotherapy for scchn * no concurrent gene therapy for scchn chemotherapy * no prior chemotherapy for recurrent or newly diagnosed metastatic disease * at least 6 months since prior induction or adjuvant chemotherapy * no more than 1 prior induction or adjuvant regimen * no prior gemcitabine or taxanes as part of induction, adjuvant, or neoadjuvant chemotherapy * no other concurrent chemotherapy for scchn endocrine therapy * not specified radiotherapy * at least 28 days since prior radiotherapy and recovered * no concurrent radiotherapy for scchn surgery * not specified other * no other concurrent therapy for scchn

Keywords: recurrent stage iv squamous cell carcinoma hypopharynx larynx lip oral cavity nasopharynx oropharynx paranasal nasal cavity metastatic neck cancer